How to Audit Your Audit Risks and Legal Exposure Management Process Before Inspectors Do

Context

In the pharmaceutical and biotechnology sectors, regulatory compliance is critical, especially when it involves controlled substances. Regulatory Affairs (RA) professionals are tasked with ensuring that organizations comply with legal frameworks governing the manufacture, distribution, and handling of these substances. A strong audit risks and legal exposure management process becomes essential in maintaining compliance and operational integrity. This article serves as a regulatory explainer manual, guiding stakeholders on how to audit their processes effectively and remain inspection-ready.

Legal/Regulatory Basis

The regulations governing controlled substances compliance vary across jurisdictions, notably in the US, EU, and UK. Understanding these laws is crucial for RA professionals tasked with compliance responsibilities.

United States

In the US, the primary regulatory authority overseeing controlled substances is the Drug Enforcement Administration (DEA). The Controlled Substances Act (CSA) serves as the legal foundation. It categorizes drugs into schedules based upon their potential for abuse, medical use, and safety. Supplementary regulations are found in the Code of Federal Regulations (CFR), specifically Title 21, which elaborates on registration, recordkeeping, and reporting requirements.

European Union

In the EU, the legal framework governing controlled substances is more fragmented, governed by multiple directives and regulations. The European Medicines Agency (EMA) ensures compliance of pharmaceuticals with EU laws, especially as outlined in the EU Regulations 726/2004 and 788/2014. The EU has its classification of narcotic drugs and psychotropic substances that align with international treaties.

United Kingdom

Post-Brexit, the UK has enforced its own Controlled Drugs and Substances (CDS) regulations, operated by the Home Office alongside the Medicines and Healthcare products Regulatory Agency (MHRA). The Misuse of Drugs Act 1971 and its amendments govern how controlled substances should be handled in the country.

Documentation

Robust documentation is the backbone of successful audit risks and legal exposure management concerning controlled substances. RA professionals should ensure meticulous recordkeeping and documentation that align with regulatory expectations.

Essential Documents

• Standard Operating Procedures (SOPs): Comprehensive SOPs should clearly outline processes from procurement to distribution and in-house handling of controlled substances.
• Inventory Logs: Regularly updated logs documenting the quantity, movement, and usage of controlled substances are essential. Records should be easily accessible for review.
• Compliance Checklists: Create checklists that align with regulatory requirements to evaluate the adherence of procedures concerning controlled substances.
• Audit Reports: Maintain and archive previous audit findings, responses, and corrective actions taken. Documentation of continuous improvements underscores an organization’s commitment to compliance.
• Training Records: Documentation demonstrating that staff have been trained in handling controlled substances as per organizational and regulatory requirements.

Review/Approval Flow

The review and approval flow involves a series of strategic steps ensuring all requirements are met before submission to regulatory agencies. Non-compliance can lead to significant audit risks and legal exposure.

Initial Assessment

Assess whether the substance in question is classified as a controlled substance under relevant regulations. Conduct a thorough examination of the legal classification before attempting to bring a product to market.

Submission Strategy

Prior to submission, RA teams should:

• Gather all required documentation outlined above.
• Determine if the submission is a new application or a variation. A new application requires a full set of data, while a variation may only require specific changes.
• Engage with relevant business units such as CMC (Chemistry, Manufacturing, and Controls) and Quality Assurance (QA) early in the process to align expectations.

Regulatory Interactions

Begin interactions with regulatory bodies well ahead of submission deadlines. Prepare for pre-submission meetings where questions may arise concerning the audit, compliance status, and overall product information.

Common Questions to Anticipate

• What constitutes compliance concerning record-keeping practices?
• How does the organization ensure waste management procedures meet regulatory expectations?
• What measures are in place to safeguard against unauthorized access to controlled substances?

Common Deficiencies

Identifying common deficiencies that regulatory authorities have encountered during inspections can vastly improve compliance and decrease audit risks associated with controlled substances.

Documentation Gaps

Failures often stem from inadequate or missing documentation. Regulatory authorities may cite organizations for:

• Insufficient records detailing the movement of controlled substances.
• Outdated or unapproved SOPs not reflective of current practices.
• Lack of training documentation as it pertains to handling controlled substances.

Inadequate Training

Staff involved in the handling of controlled substances need proper training. Agencies often identify a lack of training as a significant deficiency during audits, leading to compliance risks.

Response Delays

Timely responses to agency inquiries are crucial. Delays can lead to misunderstandings and potentially result in submission rejections or sanctions. Ensure clarity in communication pathways within the organization, particularly when responding to regulatory agencies.

Failure to Identify Classifications

Improper classification of substances can result in serious compliance deficits. RA professionals must be thoroughly educated on the classifications within their jurisdictions.

Practical Tips for Documentation, Justifications, and Responses

To ensure thorough documentation and preparedness for regulatory inspections, RA professionals should leverage the following strategies:

Documentation Best Practices

• Maintain Legibility: Ensure all records are clear, legible, and easily comprehensible.
• Regular Audits: Conduct regular internal audits to preemptively identify deficiencies. This practice helps in refining processes continually.
• Version Control: Implement strict version control for SOPs and essential documents to avoid discrepancies.

Justifying Bridging Data

Bridging data is an important aspect of variations and new applications. When justifying the use of bridging data:

• Be clear about the purpose of the data, how it relates to the controlled substance, and the regulatory context.
• Provide comprehensive statistical analysis to support your claims and ensure alignment with relevant guidelines.
• Address how it meets safety, efficacy, or quality requirements and how it can expedite the approval process.

Responding to Agency Queries

Effective communication with regulatory authorities can mitigate risks significantly. When responding to inquiries:

• Be concise yet thorough. Provide relevant data without unnecessary detail.
• Maintain a positive and cooperative tone throughout interactions.
• Address all questions individually to ensure comprehensive responses.
• Follow strict timelines provided by regulatory authorities when submitting responses.

Conclusion

In summary, an effective audit risks and legal exposure management process related to controlled substances compliance serves as a safeguard against regulatory scrutiny. By understanding the legal framework, maintaining robust documentation, engaging in proper submission strategies, and recognizing common deficiencies, RA professionals can enhance their organizations’ compliance posture. Remaining proactive in identifying risks and applying sound practices will ensure that you stay ahead of regulatory inspectors and ensure a seamless process for your organization’s pharmaceutical or biotech products.